A Phase 3, randomized, placebo-controlled, observer-blind, multi-country study to demonstrate the efficacy of a single dose of GSK’s RSVPreF3 OA investigational vaccine in adults above.

Trial Information

Start DateJune 2021
End DateTBD
Trial DurationTBD
Number of Visits8 visits
Lead CRCAdam Pawluch
StatusIn follow-up/Ongoing

For additional information
on this trial contact: